Skip to main content
Signal8

ALTERITY THERAPEUTICS LTD (ATHE)

Alterity Therapeutics Limited, an Australian biopharmaceutical firm, focuses on the discovery and development of novel drug treatments for various neurological disorders, such as Alzheimer's, Huntington's, and Parkinson's diseases. Its prominent experimental therapy, ATH434, has completed Phase I clinical trials targeting Parkinson's disease. The company is also advancing PBT2, a compound that has successfully undergone Phase IIa clinical testing for Alzheimer's disease. Established in 1997, the entity was formerly known as Prana Biotechnology Limited before rebranding to Alterity Therapeutics Limited in April 2019, and its main operations are based in Melbourne, Australia.

Sector: Pharmaceutical Preparations

Industry: Biotechnology

Alterity Therapeutics Limited logo

Alterity Therapeutics Limited

NASDAQ:ATHEHealthcare
+0.00%$1.96
CLOSED
AH$1.96+0.00%vs close
Mkt Cap$37.42M
EV-
Float16.12M
O/S19.09M
VOL13K sh
$ Vol$26K
RVOL0.06×
Inst Own2.0%
SI0.1%
Net Cash/Sh-
Dilution
Alterity Therapeutics Limited logoNASDAQ:ATHEClosed$1.96+0.00%
Short interest (FINRA)
0.1%
Oct 30 (18d)

Float 16.12M · Signal8 dilution snapshot · Aug 28, 2026

24.6K
Oct 30 (18d)prev 38.5K▼ 36.1%
1.00
Oct 30 (18d)prev 1.17▼ 14.5%
Borrow (IBKR)

The cost to borrow ATHE shares for a short sale and how many IBKR has available, from IBKR's lendable-stock file, refreshed through the session.

IBKR borrow fee and availability is included in Signal8 ProUpgrade to Pro · $40.67/mo billed annually
Off-exchange & settlement
53.4%
Nov 16 (1d)prev 45.9%▲ 7.5 pts

Off-exchange short volume is not short interest and is not a bearish signal. When a wholesaler fills a retail buy order it sells to the customer as principal and buys back in the market, and that sale is reported as short. A high reported short share is therefore characteristic of internalised retail buying, and this figure should not be read as investors positioning against the stock.

5.0K
Oct 30 (18d)prev 5.0K– 0.0%
Price, short interest & fails to deliver
Short interest · today's share basis23 settlements
Fails to deliver24 settlement dates
Latest short interest settlements (today's share basis)
DateShares short
Oct 30, 202624.6K sh
Oct 15, 202638.5K sh
Sep 30, 202626.1K sh
Sep 15, 202625.7K sh
Aug 31, 202631.5K sh
Latest fails to deliver
DateShares failed
Oct 30, 20265.0K sh
Oct 29, 20265.0K sh
Oct 23, 202613.8K sh
Oct 22, 202615.0K sh
Oct 21, 20265.0K sh

The three panels share one date axis, so a point's position is its date; each has its own value axis. Short interest is plotted on today's share basis, so the line does not step where a split does.

Off-exchange short volume
Nov 16
Latest sessions
DateReported short
Nov 16, 202653.4%
Nov 13, 202645.9%
Nov 12, 202642.9%
Nov 11, 202678.6%
Nov 10, 202652.3%
91-session median 39.5%mean 41.1%range 3.0–87.3%

130 calendar days requested; 92 sessions published. FINRA reports this at T+1 to T+2, so the latest session is not today's.

Source: FINRA Reg SHO daily short volume, summed across the NASDAQ, NYSE and Consolidated trade reporting facilities. Covers off-exchange (over-the-counter) executions only; volume executed on an exchange is not included and is not reported short here.

Off-exchange short volume is not short interest and is not a bearish signal. When a wholesaler fills a retail buy order it sells to the customer as principal and buys back in the market, and that sale is reported as short. A high reported short share is therefore characteristic of internalised retail buying, and this figure should not be read as investors positioning against the stock.

ATS venues (dark pools)

FINRA's weekly alternative trading system (dark pool) volume for ATHE: the share of off-exchange volume that traded on an ATS, and each venue by shares and trades.

The ATS venue breakdown is included in Signal8 ProUpgrade to Pro · $40.67/mo billed annually

As of the Oct 30, 2026 FINRA settlement, 24,614 ATHE shares were sold short (0.15% of a 16.12M-share float, 1.00 days to cover).